MDS-EB

Clinical trials for MDS-EB explained in plain language.

Never miss a new study

Get alerted when new MDS-EB trials appear

Sign up with your email to follow new studies for MDS-EB, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Blood cancer immune therapy trial ends early after just 2 patients

Disease control Terminated

This early-stage study tested a new drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to see if it was safe and to find the best dose. Only 2 people took part before the study was stopped early.

Matched conditions: MDS-EB

Phase: PHASE1 • Sponsor: Inmune Bio, Inc. • Aim: Disease control

Last updated May 13, 2026 16:03 UTC

MDS-EB

Get alerted when new MDS-EB trials appear

Blood cancer immune therapy trial ends early after just 2 patients